Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (Weighted Average) (2021 - 2026)

Indivior Pharmaceuticals has reported Shares Outstanding (Weighted Average) over the past 6 years, most recently at $124.0 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) changed 0.0% year-over-year to $124.0 million; the TTM value through Mar 2026 reached $124.0 million, changed 0.0%, while the annual FY2025 figure was $125.0 million, 5.3% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $124.0 million at Indivior Pharmaceuticals, down from $125.0 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $139.0 million in Q4 2022 and troughed at $320.0 in Q1 2023.
  • A 5-year average of $76.9 million and a median of $124.0 million in 2025 define the central range for Shares Outstanding (Weighted Average).
  • On a YoY basis, Shares Outstanding (Weighted Average) climbed as much as 35428471.43% in 2025 and fell as far as 7.41% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $139.0 million in 2022, then decreased by 1.44% to $137.0 million in 2023, then fell by 3.65% to $132.0 million in 2024, then decreased by 5.3% to $125.0 million in 2025, then fell by 0.8% to $124.0 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for INDV at $124.0 million in Q1 2026, $125.0 million in Q4 2025, and $125.0 million in Q3 2025.